Cargando…

Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma

Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC). Amplified in breast cancer 1 (AIB1) is frequently overexpressed in human HCC tissues and promotes HCC progression. In this study, we investigated the effects of sorafenib on AI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ming, Wang, Wei, Dan, Yuzhen, Tong, Zhangwei, Chen, Wenbo, Qin, Liping, Liu, Kun, Li, Wengang, Mo, Pingli, Yu, Chundong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045420/ https://www.ncbi.nlm.nih.gov/pubmed/27105488 http://dx.doi.org/10.18632/oncotarget.8812

Ejemplares similares

Histone acetyl transferase GCN5 promotes human hepatocellular carcinoma progression by enhancing AIB1 expression
por: Majaz, Sidra, et al.
Publicado: (2016)

Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing Notch signaling
por: Mo, Pingli, et al.
Publicado: (2014)

Histone Demethylase JMJD2D: A Novel Player in Colorectal and Hepatocellular Cancers
por: Chen, Qiang, et al.
Publicado: (2022)

Steroid receptor coactivator 3 inhibits hepatitis B virus gene expression through activating Akt signaling to prevent HNF4α nuclear translocation
por: Li, Ming, et al.
Publicado: (2019)

miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
por: Tan, Wenliang, et al.
Publicado: (2021)

Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression
por: Deng, Yuan, et al.
Publicado: (2020)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Erratum to miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
Publicado: (2022)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1
por: Wang, Kai, et al.
Publicado: (2023)

The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma
por: Zhang, Shuaishuai, et al.
Publicado: (2020)

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma
por: Li, Danyang, et al.
Publicado: (2022)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase
por: Xu, Feng-li, et al.
Publicado: (2023)

Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids
por: Awasthi, Bhuwan Prasad, et al.
Publicado: (2021)

Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma
por: Ye, Junfeng, et al.
Publicado: (2018)

Demethylase-independent function of JMJD2D as a novel antagonist of p53 to promote Liver Cancer initiation and progression
por: Li, Ming, et al.
Publicado: (2020)

miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression
por: Chen, Xianqing, et al.
Publicado: (2019)

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
por: Zhang, Qiang-Bo, et al.
Publicado: (2013)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance
por: Xia, Shunjie, et al.
Publicado: (2021)

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma
por: Cai, Mengxing, et al.
Publicado: (2023)

Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells
por: Liu, Tianhua, et al.
Publicado: (2017)

Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
por: López-Grueso, María José, et al.
Publicado: (2019)

Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib
por: Xia, Hongping, et al.
Publicado: (2017)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021)

Deficiency in steroid receptor coactivator 3 enhances cytokine production in IgE-stimulated mast cells and passive systemic anaphylaxis in mice
por: Xia, Xiaochun, et al.
Publicado: (2014)

Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
por: Kim, Young-Seon, et al.
Publicado: (2018)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma
por: Shi, Ying, et al.
Publicado: (2022)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

miR‐181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression
por: Azumi, Junya, et al.
Publicado: (2016)

MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
por: Wan, Zhong, et al.
Publicado: (2020)

Upregulation of amplified in breast cancer 1 contributes to pancreatic ductal adenocarcinoma progression and vulnerability to blockage of hedgehog activation
por: Li, Licen, et al.
Publicado: (2021)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
por: Zheng, Ruiqi, et al.
Publicado: (2023)

Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p
por: Ye, Junfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e4k0rrutk8vonr3r5vsti8hnlu